Nautilus Biotechnology (NAUT) Change in Accured Expenses (2020 - 2026)

Nautilus Biotechnology has disclosed Change in Accured Expenses across 7 years of filings, most recently posting $128000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $128000.0, down 75.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $232000.0 (up 138.41% YoY), and the FY2025 annual result was $629000.0, up 145.03% from the prior year.
• Change in Accured Expenses came in at $128000.0 for Q1 2026 at Nautilus Biotechnology, up from -$703000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $942000.0 in Q3 2025 to a low of -$703000.0 in Q4 2025.
• The 5-year median for Change in Accured Expenses is -$135000.0 (2025), against an average of $10941.2.
• Across the five-year window, Change in Accured Expenses tumbled 512.31% in 2024 and surged 4195.65% in 2025, its largest moves.
• Nautilus Biotechnology's Change in Accured Expenses stood at -$451000.0 in 2022, then advanced by 24.61% to -$340000.0 in 2023, then plunged by 96.47% to -$668000.0 in 2024, then slipped by 5.24% to -$703000.0 in 2025, then jumped by 118.21% to $128000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $128000.0 (Q1 2026), -$703000.0 (Q4 2025), and $942000.0 (Q3 2025), per Business Quant data.